435.00GBp-3.45%Mkt Cap: 67.36M GBpP/E: —Last update: 2026-05-13
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-4.35
PEG—
P/B3.55
P/S37.86
EV/EBITDA-3.86
EV/Revenue31.87
EPS (TTM)-0.99
EPS (Forward)-1.00
Cash Flow & Leverage
FCF Yield-14.84%
FCF Margin-562.06%
Operating CF-10.74M GBp
CapEx (TTM)1.57M GBp
Net Debt/EBITDA0.73
Net Debt-10.68M GBp
Technical
SMA 50496.54 (-12.4%)
SMA 200655.17 (-33.6%)
Beta0.87
S&P 52W Chg24.23%
Avg Vol (30d)1.43K
Avg Vol (10d)2.07K
Technical Indicators
RSI (14)19.3
MACD-18.4994
MACD Signal-10.9904
MACD Hist.-7.5090
BB Upper542.24 GBp
BB Middle488.20 GBp
BB Lower434.16 GBp
BB Width22.14%
ATR (14)28.18 GBp
Vol Ratio (20d)0.39x
52W Range
420.002% of range1150.00
52W High1150.00 GBp
52W Low420.00 GBp
Profitability
Gross Margin67.52%
EBITDA Margin0.00%
Profit Margin-1321.86%
Oper. Margin-710.22%
ROE-46.75%
ROA-27.57%
Revenue Growth257.90%
Earnings Growth—
Balance Sheet
Debt/Equity0.58
Current Ratio11.36
Quick Ratio10.38
Book Value/Sh1.226 GBp
Cash/Share1.686 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.15.48M
Float5.68M
Insiders60.57%
Institutions14.21%
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)1700.00 GBp
Target Range1600.00 GBp – 1800.00 GBp
# Analysts2
Company
Market Cap67.36M GBp
Enterprise Value56.70M GBp
Revenue (TTM)1.78M GBp
Gross Profit630.00K GBp
Net Income (TTM)-12.33M GBp
Revenue/Share0.1230 GBp
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees110
Last Price435.00 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINKYG1674K1013